SCHEMBL3608224

SCHEMBL3608224

O=C(Cc1csc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2C(F)(F)F)n1)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.60
HSD17B1 P14061 1/20 0.48
HSD17B2 P37059 1/20 0.48
POLB P06746 3/20 0.46
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 4/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 1/20 0.41
PDE5A O76074 1/20 0.39
FKBP1A P62942 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
MEN1 O00255 1/20 0.38
LRRK2 Q5S007 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
HTT P42858 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
F2 P00734 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7091220 0.91 HSD11B1 (0.54) HSD11B1HSD17B1HSD17B2POLBKMT2A
SCHEMBL5831585 0.84 SCN9A (0.43) HSD11B1POLBKMT2AALDH1A1LMNA
SCHEMBL5831393 0.83 GAA (0.46) HSD11B1POLBKMT2AALDH1A1LMNA
SCHEMBL3255071 0.83 HSD11B1 (0.49) HSD11B1POLBKMT2AALDH1A1LMNA
SCHEMBL3620479 0.83 POLB (0.53) HSD11B1HSD17B1HSD17B2POLBKMT2A
SCHEMBL6696959 0.82 LMNA (0.43) HSD11B1POLBKMT2AALDH1A1LMNA
SCHEMBL7192367 0.82 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2POLBKMT2A
SCHEMBL3613225 0.82 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2POLBKMT2A
SCHEMBL6699924 0.80 ALDH1A1 (0.43) POLBKMT2AALDH1A1LMNAMAPT
SCHEMBL3617614 0.80 HSD11B1 (0.78) HSD11B1HSD17B1HSD17B2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US claimed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP claimed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.